Your browser doesn't support javascript.
loading
Toward Good Read-Across Practice (GRAP) guidance.
Ball, Nicholas; Cronin, Mark T D; Shen, Jie; Blackburn, Karen; Booth, Ewan D; Bouhifd, Mounir; Donley, Elizabeth; Egnash, Laura; Hastings, Charles; Juberg, Daland R; Kleensang, Andre; Kleinstreuer, Nicole; Kroese, E Dinant; Lee, Adam C; Luechtefeld, Thomas; Maertens, Alexandra; Marty, Sue; Naciff, Jorge M; Palmer, Jessica; Pamies, David; Penman, Mike; Richarz, Andrea-Nicole; Russo, Daniel P; Stuard, Sharon B; Patlewicz, Grace; van Ravenzwaay, Bennard; Wu, Shengde; Zhu, Hao; Hartung, Thomas.
  • Ball N; The Dow Chemical Company, Midland, MI, USA.
  • Cronin MT; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
  • Shen J; Research Institute for Fragrance Materials, Inc. Woodcliff Lake, NJ, USA.
  • Blackburn K; The Procter and Gamble Co., Cincinatti, OH, USA.
  • Booth ED; Syngenta Ltd, Jealott's Hill International Research Centre, Bracknell, Berkshire, UK.
  • Bouhifd M; Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA.
  • Donley E; Stemina Biomarker Discovery Inc., Madison, WI, USA.
  • Egnash L; Stemina Biomarker Discovery Inc., Madison, WI, USA.
  • Hastings C; BASF SE, Ludwigshafen am Rhein, Germany, and Research Triangle Park, NC, USA.
  • Juberg DR; The Dow Chemical Company, Midland, MI, USA.
  • Kleensang A; Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA.
  • Kleinstreuer N; National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA.
  • Kroese ED; Risk Analysis for Products in Development, TNO Zeist, The Netherlands.
  • Lee AC; DuPont Haskell Global Centers for Health and Environmental Sciences, Newark, DE, USA.
  • Luechtefeld T; Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA.
  • Maertens A; Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA.
  • Marty S; The Dow Chemical Company, Midland, MI, USA.
  • Naciff JM; The Procter and Gamble Co., Cincinatti, OH, USA.
  • Palmer J; Stemina Biomarker Discovery Inc., Madison, WI, USA.
  • Pamies D; Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA.
  • Penman M; Penman Consulting, Brussels, Belgium.
  • Richarz AN; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
  • Russo DP; Department of Chemistry and Center for Computational and Integrative Biology, Rutgers University, Camden, NJ, USA.
  • Stuard SB; The Procter and Gamble Co., Cincinatti, OH, USA.
  • Patlewicz G; US EPA/ORD, National Center for Computational Toxicology, Research Triangle Park, NC, USA.
  • van Ravenzwaay B; Risk Analysis for Products in Development, TNO Zeist, The Netherlands.
  • Wu S; The Procter and Gamble Co., Cincinatti, OH, USA.
  • Zhu H; Department of Chemistry and Center for Computational and Integrative Biology, Rutgers University, Camden, NJ, USA.
  • Hartung T; Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA.
ALTEX ; 33(2): 149-66, 2016.
Article en En | MEDLINE | ID: mdl-26863606
ABSTRACT
Grouping of substances and utilizing read-across of data within those groups represents an important data gap filling technique for chemical safety assessments. Categories/analogue groups are typically developed based on structural similarity and, increasingly often, also on mechanistic (biological) similarity. While read-across can play a key role in complying with legislations such as the European REACH regulation, the lack of consensus regarding the extent and type of evidence necessary to support it often hampers its successful application and acceptance by regulatory authorities. Despite a potentially broad user community, expertise is still concentrated across a handful of organizations and individuals. In order to facilitate the effective use of read-across, this document aims to summarize the state-of-the-art, summarizes insights learned from reviewing ECHA published decisions as far as the relative successes/pitfalls surrounding read-across under REACH and compile the relevant activities and guidance documents. Special emphasis is given to the available existing tools and approaches, an analysis of ECHA's published final decisions associated with all levels of compliance checks and testing proposals, the consideration and expression of uncertainty, the use of biological support data and the impact of the ECHA Read-Across Assessment Framework (RAAF) published in 2015.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sustancias Peligrosas / Seguridad Química Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Año: 2016 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sustancias Peligrosas / Seguridad Química Tipo de estudio: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Año: 2016 Tipo del documento: Article